• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends

    Power Trip: A Discussion of Custom Medical Electronics

    The MDR Transition: An Opportunity for Design Change?

    Preserve and Protect: Sustainability Initiatives for Medtech Manufacturing
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—Sept. 23

    Beckman Coulter Helping Labs Comply With Annex 1 Regulation

    FDA Clears MeMed BV Direct From Whole Blood

    Biostrap Debuts Tool to Measure Stress Resilience, Heart Rate Variability

    EndoTheia Announces Positive Study Results for Endoscopic Surgery Device
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends

    Power Trip: A Discussion of Custom Medical Electronics

    The MDR Transition: An Opportunity for Design Change?

    Preserve and Protect: Sustainability Initiatives for Medtech Manufacturing
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Medtech’s Most Powerful M&A Drivers

    The Link Between Medtech and Connected Medical Devices

    Is the FTC Partly Responsible for Muted M&A Activity?

    Holistic Risk Management: Navigating the Future’s Uncertainties

    Defining End of Life for Medical Devices
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Medbio LLC

    NDH Medical Inc.

    JBC Technologies

    Johari Digital Healthcare Ltd.

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    A One-Stop-Shop, Turnkey Solution Is Paramount for Success

    How Additive and Subtractive Manufacturing Are Revolutionizing the Medical Device Industry

    Medical Device Commercialization: It’s What, Not When, to Transfer to Manufacturing

    How In Silico Simulations Can Slash Medical Device Development Risk

    The Top 7 AI Applications Transforming Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Medbio LLC

    NDH Medical Inc.

    JBC Technologies

    Johari Digital Healthcare Ltd.

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Top30

    9. Becton, Dickinson and Company

    ...

    07.26.18
    $12.1 Billion

    KEY EXECUTIVES:
    Vincent A. Forlenza, Chairman and CEO
    Thomas E. Polen, President
    Alexandre Conroy, Worldwide President, Medication and Procedural Solutions
    Nabil Shabshab, Worldwide President, Diabetes Care and Digital Health
    Christopher R. Reidy, Exec. VP, CFO, and Chief Administrative Officer
    Patrick Kaltenbach, Exec. VP and President, Life Sciences Segment
    Alberto Mas, Exec. VP and President, Medical Segment
    William A. Tozzi, Exec. VP and President, Interventional Segment

    NO. OF EMPLOYEES: 41,933

    GLOBAL HEADQUARTERS: Franklin Lakes, N.J.

    Vincent Forlenza is obviously no stranger to blockbuster deals. Two years after claiming CareFusion for $12 billion, he decided it wasn’t quite enough to keep up with the string of megamergers rocking the medical device industry to counteract widespread slowdown in revenue growth as well as healthcare provider consolidation.

    After all, he had elite (i.e., Top 30) companies to keep pace with. The medical device industry’s collective annual spit-takes began in April 2014, when orthopedic giants Zimmer and Biomet merged for a cool $13.4 billion. After medtech professionals had replaced their coffee-ruined computers, two months later, Medtronic made the announcement about a theretofore unheard of $43 billion-sized deal for Covidien. (Hopefully they had the wherewithal to turn their heads away from the screen this time.) A year later, Abbott made headlines for its $25 billion purchase of St. Jude Medical.

    Last year, megamerger fervor came right into MPO’s backyard. Franklin Lakes, N.J.-based global medical technology firm Becton, Dickinson and Company (BD) proclaimed its intent to purchase Murray Hill, N.J. based C.R. Bard (Bard)—conveniently located about an hour’s drive apart without traffic—for $24 billion last April.

    BD’s wide-ranging lineup includes products in diagnostics, diabetes care, injection, anesthesia, pharmacy, and laboratory automation. By bringing Bard into the fold, BD inherited a slew of oncology, vascular, urology, and specialty surgical offerings to tap into the market for devices used to treat vascular conditions and cancer.


    ANALYST INSIGHTS: The BD and Bard integration is still underway, without a clear decision on the success of the merger. The slow process of integration is taking its time, as both companies were behemoths to begin with, and the critical synergies they were working towards have yet to be realized. Everyone is waiting to see which businesses and business units will start to operate separately or be sold off.

    —Marissa K. Fayer, CEO and Founder, Health Equity for Women and HERHealthEQ



    Vascular products were a particularly fruitful area for Bard. In 2016, they made up nearly a third of the company’s $3.7 billion in sales. BD has said that bringing Bard’s vascular products, particularly peripherally inserted central catheters, midlines, and drug delivery ports, together with its devices to prepare, dispense, and administer drugs, will help the combined company address a wider range of medication management needs. The companies together will also offer a more comprehensive lineup of products addressing surgical site infections and catheter-related bloodstream infections.

    Bard’s portfolio will also empower BD to spread its treatment of disease states beyond diabetes. The combined company will be able to offer therapeutic products for diabetes, peripheral vascular disease, urology, hernia, and cancer.

    “We will be able to partner (with providers) on fundamental treatment processes in a way that no one else can,” Forlenza told Reuters.

    Both companies had historically garnered most of their sales from U.S. customers, but BD noted that Bard’s head start in international markets made it quite an attractive target. Bard currently has about 500 products already registered for sale overseas. Bard’s strong presence in vascular access and surgery will help to drive sales of the recently acquired CareFusion portfolio, and according to BD, Bard is among the fastest growing medical technology companies present in emerging markets.

    “The combined company will have a large and growing presence in emerging markets, including $1 billion in annual revenue in China,” BD said upon the acquisition’s announcement.

    Together, the companies have about $16 billion in revenue and is projected to enjoy annual revenue growth of 5 to 6 percent from this year to 2020, with earnings growth in the “mid-teens,” according to an investor presentation.

    With the addition of Bard, BD created a third segment to join its Medical and Life Sciences businesses—BD Interventional. Timothy Ring, the previous chairman and CEO of Bard, joined BD’s Board of Directors when the transaction closed, along with an additional, unnamed Bard director. Tom Polen, previously executive vice president and president of BD’s Medical segment, was appointed president of BD the same day as the transaction. Polen joined BD in 1999, and will oversee all three businesses.

    “This is an exciting time for BD,” he said in a company statement. “I am honored to serve in this new role as we continue our transformation into a medical technology leader focused on delivering solutions that advance the discovery, diagnostics, and delivery of healthcare globally and helping healthcare providers worldwide to improve both the process of care and the treatment of disease.”


    ANALYST INSIGHTS: With the acquisition of Bard in its rearview mirror, BD is moving forward to strengthen its core portfolios in both Life Sciences and Medical Devices. It’ll be interesting to watch their next investments and which way they see their future unfolding.

    —Dave Sheppard, Co-Founder and Principal, MedWorld Advisors



    Under the deal, BD also said it expected to cut $300 million in annual costs by fiscal 2020. Naturally, some were worried about job cuts being a part of the cost-cutting process. Thankfully, BD spokesman Troy Kirkpatrick mollified those wary of getting the axe.

    “There isn’t overlap in what we do and what Bard does,” he told USA Today. “So we are confident that the transaction will create career opportunities for their talented employees as part of a global industry leader.”

    Let’s hope BD sticks to that plan.

    The BD-Bard transaction closed three days before the end of 2017. Because BD’s fiscal year ends Sept. 30, Bard is not yet included in the company’s revenue. As such, even though BD stands poised to advance a few spaces forward in next year’s Top 30 report, the $12.1 billion of sales achieved in fiscal 2017 without Bard’s help actually represented a 3 percent loss from the year prior. The slight drop reflected the approximately 7 percent revenue decline due to BD’s shedding of its Vyaire Medical Respiratory Solutions business to private equity firm Apax Partners.

    BD’s Medical Segment—comprised of medication and procedural solutions, medication management solutions, diabetes care, and pharmaceutical systems—fell 6 percent in 2017 revenue to reach $8.1 billion as a result of the Respiratory Solutions franchise divestiture. Apart from that, all remaining product categories posted increases last year. Medication and Procedural Solutions sales rose a slight 2.5 percent to $3.5 billion, driven by boosted proceeds from infusion disposables products, particularly in the international markets. Medication Management Solutions experienced a 4.4 percent hike with $2.3 billion in revenue. Pharmaceutical Systems grew 4.8 percent to $1.3 billion thanks to heightened self-injection systems sales. Diabetes Care expanded its revenue by 3.3 percent to post $1.1 billion, primarily as a result of improved pen needle sales in both the United States and emerging markets.

    In a move that was overshadowed by the blockbuster Bard buy, BD closed the book on its purchase of Israeli infusion pump systems manufacturer Caesarea Medical Electronics (CME) last April. BD had previously gained a 40 percent ownership interest in CME upon acquiring CareFusion, and obtained the remaining 60 percent stake in the deal.

    In November 2016, BD launched the U-500 Insulin Syringe, the first insulin syringe for diabetics taking Eli Lilly & Company’s Humulin U-500 insulin. It features a 6 mm x 31-gauge needle, the shortest of its kind available at the time of launch. The short needle minimizes risk of intramuscular injection and delivers the insulin into subcutaneous tissue. It also features clearly marked dosage labeling to prevent confusion and incorrect dosing.

    The NeoPak 2.25 mL prefillable glass syringe hit the U.S., European, and Japanese markets a month later. It is specially designed for biopharmaceutical manufacturers making high-value, sensitive biologic drugs requiring higher quality levels and performance to treat chronic diseases like rheumatoid arthritis, psoriasis, lupus, and severe asthma. Neopak 2.25 mL was also designed to diminish unwelcome interactions, for example drug degradation or aggregation, between the primary container and drug.

    Last January during the 53rd Annual Society of Thoracic Surgeons (STS) Meeting, the PleurX catheter system earned FDA 510(k) clearance to be used in specific non-malignant pleural effusions etiologies, including congestive heart failure. Initially approved in 1997 for managing malignant and recurrent pleural effusions, the new indication expanded the system to patients suffering from congestive heart failure and cardiogenic effusions.

    “The system helps patients take control of their therapy by enabling them to manage fluid from pleural effusions outside of the hospital,” said Jim Leitl, BD’s worldwide vice president and general manager for Infection Prevention, V. Mueller, and Interventional Specialties. “Patients now have the option to potentially avoid the mental and physical toll of undergoing an additional hospital procedure.”

    BD’s line of Snowden-Pencer 3.0 mm laparoscopic ergonomic take-apart instruments gained FDA clearance for laparoscopic surgery last June. The new instruments used in micro-laparoscopic surgery function like their 5.0 mm counterparts, with jaw lengths that mirror standard laparoscopic instruments. That way, surgeons can use a less invasive approach without compromising functionality. The new line’s launch gave BD one of the most customizable portfolios of 3.0 mm micro-laparoscopic instruments available—26 different jaw patterns, two different lengths (24 cm, 36 cm) and six take-apart handles, provide 312 combinations to target procedures in multiple specialties.

    Last September, BD launched the Ultra-Fine micro pen needle 6 mm x 32G for leading pen injection devices. The shorter needle rounded out BD’s Ultra-Fine pen needle offering, which now includes 4mm x 32G, 5mm x 31G, 6mm x 32G, 8mm x 31G and 12.7mm x 29G. The needle helps prevent diabetic patients from injecting insulin into the muscle, and also ensures a comfortable injection experience due to micro-bonded needle lubrication for less friction.

    BD’s Life Sciences business—which contains preanalytical systems, diagnostic systems, and biosciences offerings—rose a modest 4.2 percent to achieve $4 billion in 2017 revenue. Sales of preanalytical systems rose 4.4 percent to $1.5 billion. Diagnostics systems earned $1.4 billion, growing 5.9 percent from the year prior. Biosciences revenues posted $1.1 billion of sales, expanding 1.8 percent. Global sales growth was stimulated by boosted income from safety-engineered products, increased earnings from microbiology and molecular platforms (particularly in emerging markets), and augmented biosciences unit proceeds in developed markets.

    On Halloween 2016, the MAX Vaginal Panel, a first-of-its-kind molecular test to detect the most common causes for vaginitis, won FDA market authorization. The assay is the first multiplex, real-time PCR test authorized to diagnose both vaginitis and vaginosis in women exhibiting vaginal infection symptoms. With the MAX Vaginal Panel’s introduction, labs and clinicians can use a single test to screen patients for microorganisms responsible for Bacterial Vaginosis, Trichomaniasis, and Vulvovaginal Candidiasis (yeast infection). The market authorization was granted under the de novo pathway.

    Last January, BD launched Precise whole transcriptome analysis (WTA) kits to identify and quantify genetic information in individual cells for genomics-based research. WTA is usually used to determine if an under- or over-expression of certain genes are indicative of a specific set of physical characteristics, or phenotype. The kits include specialized agents to extract RNA molecules from individual cells, then “tag” each with a unique molecular signature to count individual instances of each molecule. Quantifying RNS cells comprising genes helps determine what makes healthy cells different from diseased cells.

    The FACSVia flow cytometer system achieved FDA clearance last April. With a compact design that fits on a benchtop or within a hood, the system contains a leucocount reagent assay used in residual white blood cell enumeration. The BACSVia system provides blood banks and clinical labs with a cell analysis solution to help determine and quantify the presence of residual white blood cells in their blood products.

    The company earned FDA 510(k) clearance for the MAX extended enteric bacterial panel last June. The molecular test targets infectious diarrhea by detecting harmful intestinal bacteria. It is the latest offering in the MAX enteric assays portfolio, which help to detect and diagnose acute gastroenteritis. It joins the MAX enteric bacterial and parasite panels to allow individualized testing based on the patient’s symptoms and health history.

    A month later, the FACSLyric flow cytometer system won FDA clearance for use with the firm’s Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency. FACSLyric combines a benchtop-sized instrument with software, reagents, and services in order to ensure accurate, reliable, and repeatable results. FACSLyric supports the Multitest 4-Color assays and the Multitest 6-Color TBNK assay, whose metrics can be used together to evaluate the immunology of those who may have immune deficiency.

    Four days before the close of BD’s fiscal year, it launched the Phoenix CPO (carbapenamase-producing organisms) detect test in Europe. CPOs, specifically carbapenem-resistant Enterobacteriaceae (CRE), are a prominent public health threat due to their resistance to nearly all available antibiotics, and are included on the World Health Organization’s priority pathogen list as critical threats. According to a 2015 study in the Journal of Antimicrobial Chemotherapy, rates of mortality associated with certain CPO infections vary widely from 22 to 72 percent. The Phoenix CPO detect test, included on Phoenix gram-negative panels, identifies CPOs and provides the Ambler classification of the enzyme produced in under 36 hours. That way, hospitals and labs can categorize antimicrobial resistance and rapidly implement infection control measures and select the appropriate antibiotics.

    Last August, the FDA began an investigation that sought to determine a link between BD blood collection tubes and faulty results for Magellan Diagnostics’ LeadCare lead testing systems. Last May, Magellan had previously received an FDA warning for inaccurate results reported on blood samples. Prior to that, Magellan had said inaccurate results may be linked to a change in the composition of the tops of certain BD blood collection tubes. At the time, the FDA said they found several violations at BD’s New Jersey facility, but “have not determined that the BD tubes or any other brand of tube is linked to the cause of the inaccurate lead test results,” and “…are continuing to aggressively investigate the matter.”

    The investigation ultimately led to a January 2018 warning letter citing that the company marketed certain BD Vacutainer blood collection tubes with significant changes to the rubber stoppers without required FDA clearance or approval, and failed to submit medical device reports to the FDA within the required timeframe. The inspection also revealed BD did not evaluate or investigate the previous complaints regarding Magellan’s lead testing systems. The company recalled the tubes in question this past March. The issue was discovered to be a chemical in the rubber tube stopper that interferes with the accuracy of Anodic Stripping Voltammetry testing methodology, which is used in Magellan’s LeadCare test.
    Related Searches
    • forward
    • genes
    • heart
    • quality
    Suggested For You
    Babson Diagnostics Raises $31 Million in Series B Funding Babson Diagnostics Raises $31 Million in Series B Funding
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Vicarious Surgical Business Combination with D8 Holdings Approved Vicarious Surgical Business Combination with D8 Holdings Approved
    FDA Issues EUA for BD Veritor At-Home Covid-19 Test FDA Issues EUA for BD Veritor At-Home Covid-19 Test
    BD Launches FACSymphony A1 Benchtop Cell Analyzer BD Launches FACSymphony A1 Benchtop Cell Analyzer
    BD Names Christopher DelOrefice as EVP and CFO BD Names Christopher DelOrefice as EVP and CFO
    BD Acquires Velano Vascular BD Acquires Velano Vascular
    Global Diabetes Care Devices Market to Garner $39.4B by 2027 Global Diabetes Care Devices Market to Garner $39.4B by 2027
    BD to Build $200 Million Manufacturing Facility in Zaragoza, Spain BD to Build $200 Million Manufacturing Facility in Zaragoza, Spain
    Abbott Abbott's Navitor TAVI System Gains CE Mark
    BD Announces CE Marked Assay for HPV Screening from At-Home Self-Collected Samples BD Announces CE Marked Assay for HPV Screening from At-Home Self-Collected Samples
    BD to Spin Off Diabetes Care Biz BD to Spin Off Diabetes Care Biz
    CerTest Biotec & BD Add Saliva to the Visasure SARS-CoV-2 Detection Kit CerTest Biotec & BD Add Saliva to the Visasure SARS-CoV-2 Detection Kit
    BD Receives 510(k) Clearance for Pristine Catheter BD Receives 510(k) Clearance for Pristine Catheter
    BD to Invest $65M in Tucson, Arizona Supply Chain Hub BD to Invest $65M in Tucson, Arizona Supply Chain Hub

    Related Breaking News

    • Diagnostics
      Babson Diagnostics Raises $31 Million in Series B Funding

      Babson Diagnostics Raises $31 Million in Series B Funding

      Money will be used to help drive commercialization of customer-first, highly accessible diagnostic blood testing.
      Business Wire 09.20.21

    • Medical Devices Market to Top $671.49 Billion by 2027

      Medical Devices Market to Top $671.49 Billion by 2027

      Wearables and rising cases of chronic diseases will help fuel growth, industry data predicts.
      Precedence Research 09.16.21

    • Surgical
      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical Business Combination with D8 Holdings Approved

      Vicarious Surgical to debut on NYSE as disruptive next-gen surgical robotics company.
      Business Wire 09.16.21


    • Diagnostics
      FDA Issues EUA for BD Veritor At-Home Covid-19 Test

      FDA Issues EUA for BD Veritor At-Home Covid-19 Test

      The test does not require a prescription, a laboratory or a long wait for results.
      BD 08.26.21

    • Diagnostics
      BD Launches FACSymphony A1 Benchtop Cell Analyzer

      BD Launches FACSymphony A1 Benchtop Cell Analyzer

      Brings sophisticated flow cytometry capabilities to laboratories of all sizes.
      BD 08.12.21

    Loading, Please Wait..

    Trending
    • A New Approach To Post-Market Surveillance
    • Diabetes Innovation: MIT Engineers Unveil Implantable Device With Oxygen Factory
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • Cochlear Implant Study Underway At Mayo Clinic
    • MPO's Most-Read Stories This Week—Sept. 16
    Breaking News
    • Tessy Plastics Names Stafford Frearson as President
    • HoneyNaps' AI Sleep Disorder Diagnosis Software Earns FDA Nod
    • Biomerics Finishes Expansion of Minnesota Facility
    • MPO's Most-Read Stories This Week—Sept. 23
    • Beckman Coulter Helping Labs Comply With Annex 1 Regulation
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Superior Subtractive Solutions for Machining Medtech
    • Medical Device Industry Experts' Thought on Assembly & Automation
    • Power Trip: A Discussion of Custom Medical Electronics
    • The MDR Transition: An Opportunity for Design Change?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    GOED Releases Sustainability Report for Omega-3s Industry
    ABC’s Journal HerbalGram Celebrates 40th Anniversary
    Curcumin May Be As Effective as PPI for Indigestion
    Coatings World

    Latest Breaking News From Coatings World

    Śnieżka Group Results are Above Expectations in 1H 2023
    ACS Reports Chameleon Inspired Building Coating
    Substrate Wetting Agent Available from BRB International
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 23
    Beckman Coulter Helping Labs Comply With Annex 1 Regulation
    FDA Clears MeMed BV Direct From Whole Blood
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Eftilagimod Cleared for Clinical Trial Use in the UK
    Veranova Names William Sanders Global VP of Chemical Development Ops
    Chime, Panolos Partner to Advance Multi-specific Therapeutic Proteins
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Investindustrial to Acquire 51% Share of Virospack
    Weekly Recap: J&J Updates Visual Identity, L’Oréal Makes Executive Changes & More
    Hailey Bieber's Rhode Expands Into Makeup
    Happi

    Latest Breaking News From Happi

    SC Johnson’s Guardian Spatial Mosquito Repellent Tool Hits Milestone in Field Testing
    Ulta Beauty’s The Joy Project Address Everyone’s Struggle with Negative Self-Talk
    Natural Products Expo East Tradeshow Closes
    Ink World

    Latest Breaking News From Ink World

    Cooper Watson Acquires Tower Products
    The Durst Group Awarded Eight 2023 PRINTING United Alliance Pinnacle Awards
    Weekly Recap: Wikoff Color, HP, INX VC Top This Week’s Stories
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PRX Market debuts, Tower Products acquired and more
    Flexo Wash to exhibit at FTA Fall Technical Conference
    Recyclable, deinkable stand-up pouch wins Gold in Germany
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Soft N' Dry Seeks to Expand Private Label Roll Out, Albis Completes Work on Line
    Lenzing Earns EU Ecolabel at Indonesian Plant
    Albis Completes Work On Extra Wide Carding, Blending Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 23
    Anika Releases RevoMotion Reverse Shoulder Arthroplasty System
    Exactech's Activit-E Polyethylene OK'ed for Vantage Total Ankle
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    HID to Showcase Future-Proof Solutions at GITEX 2023
    Weekly Recap: Mergers and Acquisitions, IEC’s IME Standards Top This Week’s Stories
    EU-Funded Collaboration Hub Aims to Mainstream Printed Electronics

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login